Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
idiopathic pulmonary fibrosis
Biotech
BMS charts 2nd pulmonary fibrosis win with LPA1 antagonist
Angling for the first-in-class title, BMS’ LPA1 drug prospect triumphed in a phase 2 study in patients with progressive pulmonary fibrosis.
Fraiser Kansteiner
Sep 11, 2023 10:05am
Galecto cans lung fibrosis med after ph. 2 fail, pivots to liver
Aug 15, 2023 7:30am
Another clinical failure sends FibroGen hunting for cost savings
Jun 26, 2023 9:42am
BMS' pulmonary fibrosis drug reduces lung function decline
May 22, 2023 1:05pm
Jounce lays off 57% of staff, agrees reverse merger with Redx
Feb 23, 2023 8:00am
Chasing Boehringer, Pliant sends stock soaring with IPF data
Jan 23, 2023 6:30am
